Dihydrocodeine 30mg tablets

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Dihydrocodeine tartrate

Pieejams no:

Mawdsley-Brooks & Company Ltd

ATĶ kods:

N02AA08

SNN (starptautisko nepatentēto nosaukumu):

Dihydrocodeine tartrate

Deva:

30mg

Zāļu forma:

Oral tablet

Ievadīšanas:

Oral

Klase:

Schedule 5 (CD Inv)

Receptes veids:

Valid as a prescribable product

Produktu pārskats:

BNF: 04070200

Lietošanas instrukcija

PACKAGE LEAFLET: INFORMATION FOR THE USER
DIHYDROCODEINE 30MG TABLETS
(DIHYDROCODEINE TARTRATE BP)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or
nurse.
- This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist or
nurse. This includes any
possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1. What Dihydrocodeine Tablets are and what they are used for
2.
What you need to know
before you take Dihydrocodeine Tablets
3. How to take Dihydrocodeine Tablets
4. Possible side effects
5. How to store Dihydrocodeine Tablets
6.
Contents of the pack and other
information
1. WHAT DIHYDROCODEINE TABLETS ARE AND WHAT THEY ARE USED FOR
Dihydrocodeine Tablets are used as a strong pain killer (known as an
opioid) for the relief of
moderate to severe pain.
2.
WHAT YOU NEED TO KNOW
BEFORE YOU TAKE DIHYDROCODEINE TABLETS
DO NOT TAKE DIHYDROCODEINE TABLETS IF:
• You know that you are allergic to dihydrocodeine tartrate, or any
of the other ingredients
(listed
in section 6 )
• You suffer from breathing problems, for example chronic bronchitis
or if you are having an
asthma attack (both are conditions of shortness of breath, wheezing
and chest tightness)
•You suffer from paralytic ileus (paralysis of the gut which stops
the movement of food
through the intestine)
• You have a head injury or suffer from increased pressure on the
brain.
Children
Dihydrocodeine Tablets are not recommended for children under 12
years.
WARNINGS AND PRECAUTIONS
• Do not take for longer than directed by your prescriber
• Taking dihydrocodeine (DHC) regularly for a long time can lead to
addiction, which might
cause you to feel restless and irritable when you stop

Produkta apraksts

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Dihydrocodeine Tablets 30mg
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains dihydrocodeine tartrate BP
30mg.
Excipients with known effect:
Lactose
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Tablet.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For moderate to severe pain.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Prior to starting treatment with opioids, a discussion should be held
with patients
to put in place a strategy for ending treatment with dihydrocodeine in
order to
minimise the risk of addiction and drug withdrawal syndrome (see
section 4.4).
The analgesic effect is not materially enhanced by increasing the dose
above that
recommended below; in severe cases the interval between doses should
be
reduced to obtain the requisite analgesic cover.
_ _
_Adults and children over 12 years: _
One tablet (30mg) every 4 to 6 hours when necessary after food.
Maximum dose
in 24 hours 180mg (6 tablets).
_Paediatric population: _
Not recommended for children under 12 years old.
_Elderly: _
The dosage may have to be reduced in elderly patients. See also
sub-section 4.4
Special warnings and special precautions for use.
Method of administration
For oral use.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or any of the
excipients listed in
section 6.1.
Respiratory depression.
Obstructive airways disease.
Acute alcoholism.
Risk of paralytic ileus.
Head injuries or conditions in which intracranial pressure is raised.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Drug dependence, tolerance and potential use for abuse
For all patients, prolonged use of this product may lead to drug
dependence
(addiction), even at therapeutic doses. The risks are increased in
individuals with
current or past history of substance misuse disorder (including
alcohol misuse) or
mental health disorder (e.g. major depression).
Additional support and monitoring may be necessary when prescribing
for
patients at ris